| | 
Part, Chapter, Paragraph
1 II, 5. 5. 3| Muenter MD, Atkinson EJ, Cha RH, O’Brien PC (1993): Levodopa
2 II, 5. 14. 8| 2005; 33: 81–92.~Selwitz RH, Ismail AI, Pitts NB (2007):
3 II, 9. 1. 1| Malone FD, Vidaver J, Ball RH, Nyberg DA, Comstock CH,
4 II, 9. 1. 1| 740-5.~ ~Escobar GJ, Clark RH, Greene JD (2006): Short-term
5 II, 9. 1. 1| 2008.~ ~Garite TJ, Clark RH, Elliott JP, Thorp JA (2004):
6 II, 9. 1. 1| 107-12.~ ~Huang DY, Usher RH, Kramer MS, Yang H, Morin
7 II, 9. 3. 2| Malone FD, Vidaver J, Ball RH, Nyberg DA, Comstock CH,
8 II, 9. 3. 2| 740-5.~ ~Escobar GJ, Clark RH, Greene JD (2006): Short-term
9 II, 9. 3. 2| 2008.~ ~Garite TJ, Clark RH, Elliott JP, Thorp JA (2004):
10 II, 9. 3. 2| 107-12.~ ~Huang DY, Usher RH, Kramer MS, Yang H, Morin
11 III, 10. 1. 3| 2002; 360: 1347-60.~Fagard RH (2005): Effects of exercise,
12 III, 10. 3. 2| Authorization of Chemicals Register~Rh~Rhodium~SAICM~Strategic
13 III, 10. 3. 2| from car catalysts using Pt/Rh or Pd/Rh. Pd/Rh catalysts
14 III, 10. 3. 2| catalysts using Pt/Rh or Pd/Rh. Pd/Rh catalysts that, due
15 III, 10. 3. 2| using Pt/Rh or Pd/Rh. Pd/Rh catalysts that, due to costs,
16 III, 10. 3. 2| more active metals than Pt/Rh catalysts (LAI 2002, IPCS
17 III, 10. 3. 2| flooding.~Levels for Pd and Rh were mainly below the detection
18 IV, 11. 6. 5| 335(13): 966-970.~ ~Brook RH, McGlynn EA et al. (2000): "
|
|
| |
